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Introduction
Hydrocephalus is the excessive accumulation 
of cerebrospinal fluid (CSF) within the cranial 
vault due to excessive production or inadequate 
absorption. The management of hydrocephalus 
in developing nations is hindered by significant 
economic constraints and delays in treatment 
- most patients in fact do not present for at 
least seven months after the onset of clinical 
symptoms (1). CSF shunts are expensive 
and not always available, but can be used to 
treat hydrocephalus regardless of etiology. 
The management of hydrocephalus and the 
complications associated with its treatment 
require considerable surgical judgment and a 
life-long approach to patient follow-up.
Demographics
The prevalence of hydrocephalus in developed 
nations is estimated as 0.9-1.2/1000 (2). No 
reliable estimate is available in the African 
literature, but its incidence is likely higher 
because of untreated/poorly treated neonatal 
meningitis and nutritional deficiencies.
Aetiology & pathophysiology
Cerebrospinal fluid (CSF) is produced 
predominantly by the choroid plexus of the four 
cerebral ventricles, at a rate of 20 ml/hour. It 
flows via the foramina of Luschka and Magendie 
into the subarachnoid space, and is absorbed 
by the arachnoid villi into the venous system 
via the superior saggital sinus. Hydrocephalus 
has been categorized as communicating or non-
communicating: the former is due to failure of 
CSF absorption by the arachnoid villi, whereas 
the latter involves obstruction of CSF flow into 
the subarachnoid space. A small minority of 
cases exhibit excessive production of CSF — 
most commonly secondary to a choroid plexus 
papilloma.
In developed nations, hydrocephalus 
has historically been most commonly due to 
myelomeningocele, with the post-hemorrhagic 
hydrocephalus of prematurity becoming at least 
as common in recent years (2). Some reports have 
suggested that in central Africa the most common 
causes of hydrocephalus are —neural tube defects 
and congenital aqueductal stenosis (3). Similarly, 
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Figure 1: Aetiology of hydrocephalus in Uganda
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in Zambia, the ratio of congenital to “post-
meningitic” hydrocephalus has been reported to be 
2:1 (4). In contrast, a well-documented prospective 
series in East Africa has shown the etiology of 
hydrocephalus to be 57% post-infectious, 29% non 
post-infectious, and myelomeningocele (Figure 1). 
Thus, neonatal meningitis /ventriculitis is likely 
the most common cause of hydrocephalus in East 
Africa (1).
Despite the prevalence of malaria in Africa and 
case reports of associated hydrocephalus, there 
is no clear relationship between its cerebral form 
and subsequent hydrocephalus (5). On the other 
hand the pathophysiology of hydrocephalus in 
the setting of myelomeningocele is multifactorial: 
it may be secondary to obstruction at the 
aqueduct, ventricular outlet, craniocervical 
junction, or arachnoid granulations.
Clinical presentation
The clinical presentation of hydrocephalus 
is characterized by signs and symptoms of 
increased intracranial pressure (ICP). Symptoms 
may include: headache, vomiting, failing vision, 
drowsiness, fatigue, deteriorating mental 
function, and enlarged head circumference. 
Signs include: wide tense fontanel, papilloedema, 
reduced visual acuity, failure of upward gaze (the 
sunsetting sign), general clumsiness, dyspraxic 
gait, and increasing head circumference. Older 
children will not present with increased head 
circumference, and often complain of the classic 
triad: headache, vomiting and lethargy (Table 1).
 




















Clinical examination is the most readily available 
investigation for the diagnosis of increased 
ICP, shunt malfunction or infection. All shunts 
should be examined and manipulated, although 
pumping of the shunt is not a reliable test of 
malfunction. Nevertheless, classic teaching 
suggests that a reservoir that is difficult to depress 
(or refills instantaneously) may indicate distal 
obstruction whereas slow filling of the reservoir 
may indicate obstruction proximally (6).
Cranial ultrasonography (US) is an essential 
diagnostic tool in developing countries: it can 
readily assess ventricular size with minimal 
training, and is relatively inexpensive. Depending 
on operator skill, the size of the fourth ventricle 
can be assessed on US as a proxy indication 
of the patency of the aqueduct. This may be 
particularly relevant in stratifying patients 
for treatment with prosthetic shunts versus 
endoscopic third ventriculostomy (ETV). Serial 
US imaging may be appropriate in patients with 
an equivocal presentation of increased ICP prior 
to subjecting them to shunt revision. All children 
with shunts should be followed up regularly, 
including baseline US within three months of 
surgery. Although acute changes from baseline 
may help in the subsequent diagnosis of shunt 
failure, up to a third of patients will not exhibit 
any evidence of ventriculomegaly (6).
Both computed tomography (CT) and 
magnetic resonance imaging (MRI) are excellent 
modalities, but their routine use is prohibited 
by cost in developing nations. Nevertheless, CT 
may be necessary in assessing the ventricular 
size in older children with closed fontanels 
noted. Evidence of increased ICP in children with 
closed fontanels can also be obtained through 
direct measurement of CSF pressure by lumbar 
puncture: the CSF column height is measured in 
a piece of intravenous (IV) tubing connected to 
the spinal needle via a 3-way stopcock.
Although rarely required, a “shuntogram” 
of the entire radiopaque shunt tract via a series 
of plain X- rays encompassing the skull, chest 
and abdomen is helpful when there is clinical 
suspicion of possible shunt migration or 
discontinuity (7).
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Documentation of shunt infection or 
ventriculitis may require culturing of CSF 
samples from the ventricles (in the neonate) or 
from the shunt reservoir itself. There is a small 
but real risk of CSF contamination with each 
diagnostic tap. A value of 50-100 white cells/
mm3 is considered indicative of an infected 
CSF, as is elevated protein, decreased sugar, 
and naturally the presence of bacteria on Gram 
stain. A bloody tap may erroneously elevate 
the white cell number. Any febrile child with 
a shunt should be examined for the possibility 
of other common febrile illnesses, especially if 
they are beyond 6 months post-shunt insertion. 
Malaria, otitis media, and viral gastroenteritis 
should be excluded, in addition to the possibility 
of urinary tract infection particularly in those 
with spina bifida and bladder dysfunction (6).
Management
The definitive management of hydrocephalus 
at present remains surgical. The diuretic 
acetazolamide has been shown to decrease CSF 
production in animal and human studies (8), 
but is of temporary benefit and should only 
be used in the palliative setting or in equivocal 
cases until a definitive diagnosis can be made. 
It has also been used in post-hemorrhagic 
hydrocephalus of the newborn as a temporizing 
maneuver to avoid shunting (9).
Ventriculo-peritoneal shunt: The most common 
surgical intervention to treat hydrocephalus is 
the insertion of a shunt through the skull and 
cortical mantle into the ventricle, with the distal 
catheter placed into a physiologic drainage 
basin, typically the peritoneal space (ventriculo-
peritoneal or VP shunt). Other sites for CSF 
diversion include the right atrium and the pleural 
space. The advantage of a CSF shunt is that it is 
beneficial in nearly all types of hydrocephalus—
regardless of etiology.
CSF shunts usually contain three parts: 
a ventricular catheter, a valve, and a distal 
catheter. Most valves are designed to allow for 
sampling via needle puncture. The so-called 
“differential pressure valves” use the gradient 
between the ventricle and the tip of the distal 
catheter to effect flow. “Medium pressure” 
valves are those which drain CSF if the pressure 
gradient is >10 mm Hg, and are used most 
commonly. Although many different valve 
designs exist including “siphon limiting”, “flow 
limiting”, and “programmable” valves (whose 
settings can be changed using an external 
magnet) there is limited evidence for their 
benefit. A large randomized trial demonstrated 
no difference in time to first shunt failure in the 
treatment of children with newly diagnosed 
hydrocephalus when comparing a standard 
differential pressure valve compared to two 
other higher generation valves (10). Similarly, 
the use of an adjustable shunt was not shown 
to be of any benefit in terms of overall survival 
(11). Finally, and of most relevance to the 
developing world, there is good evidence 
from a prospective randomized controlled 
trial demonstrating that the Chhabra® shunt 
(made by Surgiwear in India) is equivalent to 
its common Western counterpart in incidence 
of shunt complications, despite it being almost 
1/20 the cost (12). The Chhabra shunts are 
made available for free to qualifying centres 
through the International Federation of Spina 
Bifida and Hydrocephalus (www.ifglobal.org). 
In extreme situations, a piece of IV tubing or a 
sterile Silastic® feeding catheter can be used as 
VP shunts, but these non-valved alternatives 
are associated with frequent complications and 
not recommended.
Alternative CSF drainage sites:  Pleural shunts are 
rarely required, but can be placed via the 4th 
to 6th intercostal space at the anterior axillary 
line into the pleural cavity, with care to avoid 
placement into lung parenchyma or chest wall. 
The associated CSF effusion and iatrogenic 
pneumothorax resolve conservatively in 
almost all patients. Ventriculoatrial shunts are 
rarely performed because of complications of 
cor pulmonale, shunt nephritis, and catheter 
embolization. They require intraoperative 
ultrasound or fluoroscopy to document catheter 
placement into the atria via the internal jugular 
vein. We do not recommend their use.
Endoscopic third ventriculostomy: The morbidity 
of the life-long shunt has created interest in 
the use of endoscopic third ventriculostomy 
(ETV) a procedure that can effectively treat 
hydrocephalus without insertion of any foreign 
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body. The principles of placement of an ETV 
include: frontal access, ventricular cannulation, 
insertion of a rigid or flexible neuroendoscope 
into the 3rd ventricle via the lateral ventricle 
and the foramen of Monroe. A fenestration is 
made in the base of the third ventricle between 
the infundibular recess and the mamillary 
bodies. This is commonly performed using a 
combination of electrocautery and a balloon 
dilator, thus creating a cerebrospinal fluid 
fistula between the subarachnoid space and the 
3rd ventricle (7). More recently, the concurrent 
performance of cauterization of the choroid 
plexus has been introduced as means of 
increasing shunt avoidance.
Classically, ETV was used for older children 
or adults with congenital aqueductal stenosis. 
Working in Uganda, Dr. Benjamin Warf has 
convincingly demonstrated however that ETV 
is a reasonable option for all children greater 
than 1 year of age (irrespective of hydrocephalus 
etiology) with a shunt avoidance rate of 80%. In 
addition, with the use of cranial US and direct 
endoscopic visualization of the aqueduct, he 
stratified younger children based on aqueductal 
patency, and has demonstrated 70% success in 
those <1 year of age who have a post-infectious 
obstruction of the aqueduct. In addition, the 
use of ETV in combination with choroid plexus 
cauterization has increased shunt avoidance from 
35 to 76% in children with myelomeningocele, 
and from 20% to 71% in children <1 year of age 
with a non-post-infectious hydrocephalus and 
an open aqueduct (1).
Performance of ETV is beyond the scope of 
this review, and requires adequate mentoring 
by an experienced surgical team and significant 
technical support for maintaining the endoscopic 
system. Although the avoidance of a shunt (and 
the accompanying morbidity and mortality 
of shunt failure) in the developing world is a 
reasonable goal, the additional safety of ETV 
has not yet been proven in the long term, and 
most authors counsel that the same life-long 
follow-up is required in either case (2).
Postoperative Complications
Post-operative complications of shunt insertion 
can generally be classified as mechanical or 
infectious.
Mechanical shunt failure: Mechanical shunt failure 
can occur through proximal obstruction, distal 
obstruction, component separation/fracture/
migration or excessive CSF drainage (2).
Proximal or distal obstruction generally 
presents with signs and symptoms of increased 
ICP, whereas infectious failure presents with fever, 
redness or swelling at the surgical site, drainage 
of pus or CSF from the wound, nuchal rigidity, 
abdominal pain or peritonitis. Shunt obstruction 
in older patients often presents with headache, and 
is not associated with pain along the shunt tract 
(2). Although the signs and symptoms of shunt 
failure have been examined empirically, there is no 
ideal diagnostic test (2). Importantly, the opinion 
of parents is of greater diagnostic accuracy than 
that of referring clinicians (2): thus caregivers’ 
opinions of their child’s shunt function should not 
be dismissed lightly. In addition, children tend 
to present with similar manifestations during 
episodes of repeated shunt failure (13). Revision 
of a non-infected, but obstructed shunt should 
generally be approached from the cranial incision 
as obstruction is more common at the ventricular 
limb, and both ventricular and abdominal limbs 
can be tested in sequence from this location after 
they have been disconnected from the valve. 
Non-functioning ventricular catheters that are 
adherent can be removed by gentle traction under 
most circumstances, but we do not advocate more 
aggressive measures: rather, a new shunt should 
be placed at an alternative site.
Passage of a new peritoneal shunt down 
an established fibrous tract is occasionally 
possible as long as shunt infection has been 
ruled out preoperatively. Routine CSF culture 
in the absence of infectious signs or symptoms 
is not recommended as positive cultures in 
this setting are not predictive of subsequent 
infection (14).
Infectious shunt failure: Shunt infection is widely 
believed to be caused by contamination at the 
time of surgery, with occasional infections 
caused by later wound breakdown either due 
to CSF fistulisation or skin breakdown over 
hardware (2). Most shunt infections usually 
present within 3 months of shunt insertion, 
and almost all within six months (2). The 
rate of shunt infection in North America is 
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approximately 8-10% (15) with some series 
reporting less than 1% (16), but in Africa is 
likely higher (17). The most common organisms 
grown are consistently S. epidermidis (~40%), 
followed by S. aureus (~20%) (18).
Risk factors for shunt infection include pre-
maturity (19,20), elaborate shunt configurations, 
multiple separate shunts, previous shunt infec-
tion, surgical inexperience, myelomeningocele, 
post-operative CSF leak, and longer duration of 
surgery (21).
Common techniques to avoid shunt infection 
include the use of generous skin preparation, 
meticulous and consistent surgical technique, 
and preoperative prophylactic antibiotics 
(22). Although there is significant world-wide 
heterogeneity with regards to choice of antibiotic 
(23), we recommend ceftriaxone or cefazolin 
upon induction of anaesthesia. A Cochrane 
review in 2006 has supported the use of antibiotic 
prophylaxis in reducing shunt infection, with 
no evidence of benefit beyond 24 hours (24). 
As advocated by Faillace et al., the avoidance 
of shunt-to-skin contact resulted in a three-fold 
decrease in shunt infection rates from 9.1 to 2.9% 
(25). As mentioned earlier, valve design does not 
appear to have any effect on shunt infection. The 
surgeon should develop a consistent routine using 
the same equipment, and a meticulous approach: 
some authors have reported very low infection 
rates using similar techniques (26). Finally, shunts 
should not be relegated to the most inexperienced 
member of the team. We agree with the author 
who suggested: “Although less glamorous than 
other neurosurgical cases, shunting procedures 
deserve no less attention to detail” (27).
Because conventional antimicrobial 
techniques are not effective in treating the 
bacterial biofilms that affect most neurosurgical-
related device infections, all infected shunts 
should be removed (28). This is combined with 
the insertion of an external ventricular drain 
with ongoing systemic and optional intrathecal 
antibiotics, with replacement of the shunt 10-14 
days later with preoperative confirmation of a 
sterile CSF. Treatment with antibiotics alone has 
a high failure rate, and is probably only relevant 
in the high-risk surgical patient.  Vancomycin 
has poor CSF penetration by IV route, and thus 
preservative-free ventricular vancomycin has 
been commonly used to treat shunt infections 
despite the incomplete understanding of side 
effects and toxicity (29).
Shuntalgia syndrome: This unusual shunt 
complication presents with focal discomfort 
around the shunt site without swelling, 
fluctuance or redness. There may be tenderness 
along the shunt itself, and there is usually a hard 
fibrotic sheath of scar tissue around the shunt. It 
is common in adolescents, and should generally 
be treated with conservative measures although 
narcotic analgesics have been required in some 
cases (2).
Shunt separation / fracture / migration: Although this 
occasionally occurs within the first few months of 
surgery it is thankfully rare. Clinical examination 
and if necessary a shunt series of plain radiographs 
along the entire shunt tract is sufficient to confirm 
the diagnosis. The phenomenon of arrested 
hydrocephalus (whereby a child develops true 
shunt independence) is rare: 80% of children 
who have stable ventricles despite a disconnected 
shunt have a raised ICP (30). Therefore most non-
functioning shunts should be revised.
Hollow viscus perforation: Perforation of virtually 
every hollow viscus by the peritoneal catheter 
has been described, but is usually diagnosed 
by observation of the catheter protruding from 
the anus. The risk of hollow viscus perforation 
has been estimated at 1/1000 shunt years (31). 
Remarkably, peritonitis is rarely a presenting 
feature, likely due to the gradual erosion of 
the shunt through bowel. Treatment is similar 
to other cases of shunt infection and involves 
removal of the shunt in its entirety via a single 
valve-site incision in the cranium, external 
drainage for 10-14 days with intrathecal or IV 
antibiotics followed by shunt replacement. 
Laparotomy is reserved for the rare case of 
peritonitis, but is not routinely required to 
remove the shunt.
Prognosis and Outcomes
The mortality associated with shunt placement 
is about 0.1%, but shunt failure is more lethal 
at 1-4% -especially in the African setting with 
its frequent difficult and delayed access to 
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health care. The operative risk of ETV is still 
being defined, but perioperative mortality may 
approach 1% (2). Shunts fail due to mechanical 
or infectious causes at a rate of 30-40% within 
the first year after placement (13), 15% within 
the 2nd year, and 1-7% per year thereafter (2). 
Shunt infection is associated with reduced IQ 
and school performance, and a higher risk of 
future shunt infection (32). Although the risk of 
ventriculitis is reduced after ETV, it is not zero.
Prevention
In East Africa, the single most common cause of 
hydrocephalus is infection of the CNS, usually 
via neonatal meningitis or ventriculitis. Neonatal 
sepsis is common and is exacerbated by the 
lack of skilled perinatal care for the majority 
of births in Africa. Newborns presenting with 
febrile illness should ideally receive appropriate 
diagnostic tests and directed antibiotic therapy, 
and not just empiric therapy for presumed 
malaria. Efforts at improving perinatal care 
in developing countries will undoubtedly 
help to reduce the incidence of post-infectious 
hydrocephalus. The association of neural tube 
defects with hydrocephalus also mandates 
their prevention. There is excellent evidence to 
counsel for the use of 0.4 mg of folic acid daily in 
all women of child-bearing age, and 4 mg daily 
for mothers with previous children born with 
neural tube defects as a means of prevention 
(33).  The fortification of wheat flour with folate 
has been met with success in many developed 
countries (34,35) and there is increasing advocacy 
for it in the developing world (36).
Ethical Issues
There is a paucity of literature concerning the 
ethics of non-treatment of hydrocephalus, and 
issues surrounding resource allocation in the 
treatment of this disease. Informed consent of 
the patient and family should address the need 
for life-long ongoing surveillance of any child 
treated for hydrocephalus, the risk of shunt 
infection, shunt failure, and death. Families 
should be educated regarding signs of infection 
or shunt failure at the first admission.
Although we are not aware of any guidelines 
regarding assessment of medical futility in 
the setting of hydrocephalus, we recommend 
extreme caution in shunting children with head 
circumferences> 60cm, or in patients who have 
non-healing pressure sores on the cranium. 
For many of these children, aggressive surgical 
intervention is futile, and family resources are 
challenged by lengthy or repeated admissions.
Lastly, because of the higher incidence of 
hydrocephalus in developing nations, it is 
likely that research efforts will continue to be 
directed in this area. As in any research setting, 
attention to a meticulous informed consent 
process is required, particularly for those who 
are more vulnerable because of poverty or 
lower education.
Recommendations
1. Early treatment of hydrocephalus with 
ventriculo-peritoneal shunts remains the best 
method of preventing life-long disability from 
increased intracranial pressure in Africa.
2. Clinical symptoms and signs and cranial 
ultrasound are sufficient for the diagnosis and 
management of children with hydrocephalus.
3. Simple valved shunts such as the Chhabra® 
shunt are as effective as more sophisticated 
devices and save significant resources.
4. Shunt placement must be a thoroughly 
sterile procedure performed by skilled, 
experienced surgeons.
5. Both mechanical and infectious shunt 
complications can be significantly reduced 
through meticulous technique and experience.
6. Children shunted for hydrocephalus must 
be followed up for life and have rapid 
access to health care facilities in the case of 
complications.
7. Endoscopic third ventriculostomy shows 
significant promise for avoiding shunt 
morbidity in children with hydrocephalus, 
but remains limited by technology and skill.
8. Besides early diagnosis, prevention of 
hydrocephalus can be accomplished 
through efforts directed at the correct 
management of neonatal infections and 
folic acid supplementation for all women of 
child-bearing age.
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